ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
ProMIS Neurosciences Inc. reported a third-quarter 2026 net loss of $8.16 million, compared with $11.58 million a year earlier; nine-month net loss was $28.14 million versus $29.05 million. Cash was $44.07 million at September 30, following $70.1 million of net proceeds from its January 2026 private placement. Operating cash use in the first nine months was $32.15 million, versus $18.84 million in 2025.
Management expects existing cash and short-term investments to fund operations and capital expenditures through 2027 under its current operating plan, while saying further funding will be needed for future clinical activities. The estimate depends on assumptions, and capital could be exhausted sooner.
In blinded six-month interim results from 136 PRECISE-AD participants who received at least six months of treatment, PMN310 had no ARIA-E reported as of the data cutoff and 4.4% ARIA-H, all mild and asymptomatic. Biomarker declines from baseline were observed in 68.5% of patients for plasma pTau217 and 62.5% for CSF MTBR-tau243. ProMIS cautioned these observations do not determine efficacy; the trial remains blinded, with topline data anticipated in the first quarter of 2027.
ProMIS Neurosciences Inc. (PMN) reported a third-quarter 2026 net loss of $8.16 million, compared with $11.58 million a year earlier, on operating expenses of $8.62 million versus $11.75 million. For the first nine months, net loss was $28.14 million versus $29.05 million. Cash was $44.07 million at September 30, 2026, compared with $6.12 million at December 31, 2025; ProMIS expects existing cash resources to fund planned operations through 2027.
Final patient visits in ProMIS’s Phase 1b PRECISE-AD study of PMN310 are nearing completion, with topline safety, biomarker and clinical efficacy data expected in the first quarter of 2027. The randomized, double-blind, placebo-controlled study evaluates intravenous doses of 5, 10 and 20 mg/kg in patients with mild cognitive impairment due to AD or mild AD. After analyzing the full data set, ProMIS plans to request an FDA meeting in 2027. Development of a subcutaneous formulation is under way, and a registrational study is anticipated toward the end of 2027, subject to FDA feedback.
In ProMIS Neurosciences Inc. (PMN), Adage Capital Management, L.P., Robert Atchinson and Phillip Gross reported beneficial ownership of 703,550 common shares, or 7.73%. Each listed shared voting and dispositive power over 703,550 shares.
The reported position is directly held by Adage Capital Partners, L.P. and includes 139,275 common shares issuable upon exercise of warrants. The 7.73% figure is based on 8,967,693 common shares outstanding as of August 13, 2026, and assumes exercise of ACP’s warrants.
ProMIS Neurosciences Inc. posted an updated corporate presentation to its website on November 11, 2026; the presentation is attached as an exhibit.
Eugene Williams, a director of ProMIS Neurosciences Inc. (PMN), purchased 26,500 common shares at $3.43 per share on November 4, 2026. His reported direct holdings after the purchase were 40,213 common shares. The transaction is described as a purchase in an open market or private transaction, and no Rule 10b5-1 plan is reported.
ProMIS Neurosciences Inc. (PMN) director Eugene Williams purchased 1,316 common shares on October 30, 2026, at $3.99 per share. The transaction was reported as a purchase in the open market or a private transaction, and his direct holdings following it were 13,713 common shares. The Rule 10b5-1 plan box was unchecked.
ProMIS Neurosciences Inc. (PMN) Chief Scientific Officer and director Neil Cashman purchased 10,000 common shares on November 2, 2026, at $3.86 per share. Afterward, he reported direct holdings of 14,532 shares. Separate indirect holdings reported were 4,122 shares by Research Capital Corporation and 664 shares by his spouse. No Rule 10b5-1 plan is reported.
ProMIS Neurosciences Inc. (PMN) reported that Chief Commercial Officer Ivana Rubino received an award of options covering 80,000 common shares on October 5, 2026. The options have an exercise price of $9.37 per share and expire on October 5, 2036. Twenty-five percent vests on October 5, 2026; the remaining shares vest monthly over the following three years, subject to continued service through each vesting date.
ProMIS Neurosciences Inc. is reported to have 7.66% of its common shares beneficially owned by Great Point Partners, LLC together with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, acting as a group. This beneficial ownership covers 736,881 common shares, including shares underlying certain warrants, with all voting and dispositive power held on a shared basis and no sole power reported.
The 7.66% figure is calculated against 9,618,424 shares of common stock deemed outstanding, consisting of 8,967,693 shares outstanding as of the company’s latest quarterly report plus 650,731 shares issuable upon exercise of warrants held by the reporting persons, subject to a 9.99% Beneficial Ownership Cap. The positions are held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd., for which Great Point serves as investment manager, and Dr. Jay and Ms. Nordahl may be deemed beneficial owners, while each disclaims ownership beyond any pecuniary interest.